The short answer
Repeated “yeast-like” symptoms should eventually shift the question from which treatment should I repeat? to was each episode actually vulvovaginal candidiasis, and if so, what organism was identified? CDC usually defines recurrent VVC as three or more symptomatic episodes in less than one year, but that count is a clinical classification—not proof that every episode of itching or discharge is Candida. 1
Confirm the diagnosis before explaining the recurrence
VVC symptoms are not specific. Itching, soreness, external burning, redness and discharge can overlap with other forms of vaginitis and with noninfectious vulvar conditions. 1 2 A familiar symptom pattern may therefore be misleading if the original episodes were never confirmed.
For recurrent or complicated presentations, CDC recommends obtaining vaginal culture or PCR to confirm the diagnosis and identify non-albicans Candida. 1 The point is not to order molecular testing reflexively, but to stop treating an unproven recurrent label as though it were already an organism result.
Species identification can matter
Non-albicans species can behave differently from the common C. albicans pattern, and Candida glabrata can be harder to recognize on microscopy because it does not form the same pseudohyphae or hyphae. 1 That makes culture or other validated identification methods more useful in selected complicated cases.
A positive Candida result still needs symptom context. Candida can be present without causing symptomatic disease, so laboratory detection should be interpreted with the clinical picture rather than treated as a self-contained diagnosis. 1
What susceptibility testing can and cannot say
CDC notes that azole resistance is becoming more common in vaginal C. albicans isolates and that susceptibility testing may be considered for symptomatic patients who remain culture-positive despite therapy. 1 This is a selected diagnostic context, not a reason to infer “resistant yeast” from treatment failure alone.
This page does not provide a suppressive regimen, boric-acid instructions, or a self-directed susceptibility-testing plan. Those are treatment decisions that depend on confirmed diagnosis, species, prior therapy and professional review.
Keep the broader differential open
Recurring vaginal or vulvar symptoms can also reflect BV, trichomoniasis, irritant or allergic reactions, skin disease, hormonal tissue change or more than one problem at once. 2 For the broader symptom pattern, see recurrent vaginal or vulvar itching. For symptoms that continue immediately after an OTC course, see itching after OTC yeast treatment.
Bottom line
The diagnostic value of “recurrent yeast” comes from confirming episodes and identifying what is actually present, not from counting similar symptoms alone. Culture, PCR, species identification and selected susceptibility testing can answer different questions, while a negative or unexpected result should reopen the differential instead of forcing the yeast label.
Medical-information boundary
This article provides general health information and does not diagnose an individual or select a patient-specific treatment. See the medical information disclaimer.
Sources
- CDC: Vulvovaginal Candidiasis. Evidence reviewed 2026-09-14. Recurrent VVC definition, culture/PCR confirmation, non-albicans species, microscopy limitations, and susceptibility context.
- CDC: Vulvovaginal itching, burning, irritation, odor or discharge. Evidence reviewed 2026-09-14. Broader vaginitis differential and testing limits when symptoms recur or persist.